{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:24:38Z","timestamp":1791559478374,"version":"4.3.4"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>QL1706 is a novel bifunctional antibody targeting PD-1 and CTLA-4 that has received conditional approval in China for cervical cancer. Its full immune-related adverse event profile remains incompletely defined. Here, we report a 61-year-old woman with endometrial clear cell carcinoma who developed severe immune-related inflammatory myopathy 4 weeks after the first cycle of QL1706 combined with paclitaxel and carboplatin. She presented with dyspnoea, generalised weakness, dysphagia and ocular motility impairment. Laboratory tests showed marked elevations in creatine kinase, CK-MB, lactate dehydrogenase and cardiac troponin T, and electrophysiological findings supported a predominant myopathic process. The final diagnosis was QL1706-associated severe immune-related inflammatory myopathy with respiratory and ocular involvement and clinically suspected cardiac involvement. Myocarditis, ocular myositis and myositis\u2013myocarditis\u2013myasthenia gravis overlap syndrome could not be definitively confirmed. The patient improved after high-dose methylprednisolone, intravenous immunoglobulin and tacrolimus. This case highlights the need for early recognition, multidisciplinary evaluation and prompt immunosuppressive treatment for severe neuromuscular immune-related adverse events during QL1706-based therapy.<\/jats:p>","DOI":"10.3389\/fonc.2026.1851665","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:22:59Z","timestamp":1787286179000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Severe QL1706-associated immune-related inflammatory myopathy presenting with respiratory dysfunction, bulbar weakness, ocular motility impairment, and suspected cardiac involvement"],"prefix":"10.3389","volume":"16","author":[{"given":"Jie","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Geriatrics, Third People\u2019s Hospital of Hangzhou","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danye","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Third People\u2019s Hospital of Hangzhou","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Third People\u2019s Hospital of Hangzhou","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Third People\u2019s Hospital of Hangzhou","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-025-01728-9","article-title":"Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study","volume":"18","author":"Zhang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103758","article-title":"Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial","volume":"92","author":"Zhang","year":"2026","journal-title":"EClinicalMedicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40265-025-02160-6","article-title":"Iparomlimab and tuvonralimab: first approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-023-01445-1","article-title":"First-in-human phase I\/Ib study of QL1706 (PSB205), a bifunctional PD1\/CTLA4 dual blocker, in patients with advanced solid tumors","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-025-05412-1","article-title":"Myocarditis induced by a novel bifunctional PD-1\/CTLA-4 combination antibody: a case report and literature review","volume":"26","author":"Wei","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1778284","article-title":"Case report: successful treatment of steroid-refractory immune checkpoint inhibitor associated myocarditis with tofacitinib","volume":"17","author":"Kong","year":"2026","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001727","article-title":"Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanoma","volume":"36","author":"Inan","year":"2025","journal-title":"Anticancer Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.803410","article-title":"Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis","volume":"12","author":"Hamada","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.121.058489","article-title":"Skeletal muscle disorders: a noncardiac source of cardiac troponin T","volume":"145","author":"Du Fay De Lavallaz","year":"2022","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12134-x","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series","volume":"271","author":"Vicino","year":"2024","journal-title":"J Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review","volume":"14","author":"Lipe","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1851665\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:23:01Z","timestamp":1787286181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1851665\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1851665"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1851665","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1851665"}}